Literature DB >> 23186214

Invasive pneumococcal disease in Australia 2007 and 2008.

Christina Barry1, Vicki L Krause, Heather M Cook, Robert I Menzies.   

Abstract

Enhanced surveillance for invasive pneumococcal disease (IPD) was conducted in all Australian states and territories in 2007 and 2008 with comprehensive comparative data available since 2002. There were 1,477 cases of IPD notified to the National Notifiable Diseases Surveillance System in Australia in 2007; a notification rate of 7.0 cases per 100,000 population. In 2008 there were 1,628 cases; a notification rate of 7.6 cases per 100,000 population. The overall rate of IPD in Indigenous Australians was almost 6 times the rate in non-Indigenous Australians in 2007 and almost 5 times in 2008. By 2008, the 4th year of a funded universal infant 7-valent pneumococcal conjugate vaccine (7vPCV) program in Australia with a 3+0 schedule, vaccine serotype IPD notification rates in those identified as non-Indigenous decreased in all age groups compared with 2002 levels, most significantly by 96% in children aged less than 5 years. However, rates of disease in non-vaccine serotypes increased by 168% in children aged less than 5 years, including a four-fold increase in the number of cases due to serotype 19A. For the Aboriginal and Torres Strait Islander population, national pre-vaccination data are not available, as the vaccine program was funded for this group from 2001. From 2002 to 2008, the proportion of disease due to 7vPCV serotypes in children aged less than 5 years decreased by 77%, while disease due to non-7vPCV serotypes increased by 76%. In Indigenous adults (≥50 years), rates of 23vPPV serotypes increased by 92%. There were 120 deaths attributed to IPD in 2007 and 113 in 2008, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remains low and reduced susceptibility to third-generation cephalosporins is rare. This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at http://www.ag.gov.au/cca.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23186214

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  8 in total

1.  Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.

Authors:  E S Littlejohn; H J Clothier; K P Perrett; M Danchin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China.

Authors:  Yu Hu; Xuejiao Pan; Fuxing Chen; Ying Wang; Hui Liang; Linzhi Shen; Yaping Chen; Huakun Lv
Journal:  Hum Vaccin Immunother       Date:  2022-03-03       Impact factor: 3.452

3.  Aboriginal and non-Aboriginal children in Western Australia carry different serotypes of pneumococci with different antimicrobial susceptibility profiles.

Authors:  Eileen M Dunne; Kylie Carville; Thomas V Riley; Jacinta Bowman; Amanda J Leach; Allan W Cripps; Denise Murphy; Peter Jacoby; Deborah Lehmann
Journal:  Pneumonia (Nathan)       Date:  2016-09-05

4.  Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective.

Authors:  Kylie Earle; Scott Williams
Journal:  Pneumonia (Nathan)       Date:  2016-06-27

5.  Genome-wide analysis of Streptococcus pneumoniae serogroup 19 in the decade after the introduction of pneumococcal conjugate vaccines in Australia.

Authors:  Rebecca J Rockett; Shahin Oftadeh; Nathan L Bachmann; Verlaine J Timms; Fanrong Kong; Gwendolyn L Gilbert; Vitali Sintchenko
Journal:  Sci Rep       Date:  2018-11-16       Impact factor: 4.379

6.  Dietary zinc and the control of Streptococcus pneumoniae infection.

Authors:  Bart A Eijkelkamp; Jacqueline R Morey; Stephanie L Neville; Aimee Tan; Victoria G Pederick; Nerida Cole; Prashina P Singh; Cheryl-Lynn Y Ong; Raquel Gonzalez de Vega; David Clases; Bliss A Cunningham; Catherine E Hughes; Iain Comerford; Erin B Brazel; Jonathan J Whittall; Charles D Plumptre; Shaun R McColl; James C Paton; Alastair G McEwan; Philip A Doble; Christopher A McDevitt
Journal:  PLoS Pathog       Date:  2019-08-22       Impact factor: 6.823

7.  Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Authors:  Daniel R Feikin; Eunice W Kagucia; Jennifer D Loo; Ruth Link-Gelles; Milo A Puhan; Thomas Cherian; Orin S Levine; Cynthia G Whitney; Katherine L O'Brien; Matthew R Moore
Journal:  PLoS Med       Date:  2013-09-24       Impact factor: 11.069

8.  General Practitioner Antimicrobial Stewardship Programme Study (GAPS): protocol for a cluster randomised controlled trial.

Authors:  Minyon L Avent; Malene Plejdrup Hansen; Charles Gilks; Chris Del Mar; Kate Halton; Hanna Sidjabat; Lisa Hall; Annette Dobson; David L Paterson; Mieke L van Driel
Journal:  BMC Fam Pract       Date:  2016-04-21       Impact factor: 2.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.